CYP2C19 Poor
1 clinical trials · Condition
| Record | Firm | Date |
|---|---|---|
| Study in Taiwanese Subjects Identified as CYP2C19 Poor and Extensive Metabolizers Receiving Rosuvastatin (NCT00766025) | AstraZeneca | 2008-09-01 |
Track CYP2C19 Poor automatically
Every clearance here is in the API, with alerts when new ones post.